Your session is about to expire
← Back to Search
Other
Ringer's lactate for Diabetic Ketoacidosis (BRISK-ED Trial)
N/A
Waitlist Available
Led By Justin W Yan, MD, MSc
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights
BRISK-ED Trial Summary
This study is evaluating whether a surgery which reduces blood flow in a stomach artery leads to significant weightloss.
Eligible Conditions
- Diabetic Ketoacidosis
BRISK-ED Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Patient recruitment rate (feasibility outcome)
Time to DKA resolution (efficacy outcome)
Secondary outcome measures
Hospital length of stay
Hyper- or hypo-kalemia post-emergency department
In-hospital acute kidney injury (Stage 2 or greater) post-emergency department
+4 moreBRISK-ED Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Ringer's lactateExperimental Treatment1 Intervention
The intervention is administration of IV Ringer's lactate. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.
Group II: Normal salineActive Control1 Intervention
The comparator is administration of IV normal saline. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.
Find a Location
Who is running the clinical trial?
Lawson Health Research InstituteLead Sponsor
658 Previous Clinical Trials
413,606 Total Patients Enrolled
Justin W Yan, MD, MScPrincipal InvestigatorLawson Health Research Institute/Western University
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger